A somatostatin analog with broad receptor coverage and high SSTR5 affinity.
Also known as: Signifor
Part of the Foundational & therapeutic peptides cluster
Overview
Pasireotide is a synthetic cyclohexapeptide somatostatin analog with roughly 40-fold greater affinity for somatostatin receptor 5 than earlier analogs. This broader receptor profile underlies its approval for Cushing's disease and acromegaly. Content here is educational only.
Source & context
Biological / chemical source: Synthetic cyclohexapeptide analog of somatostatin
Primary research or clinical context: Approved for Cushing's disease and acromegaly
Broadened receptor profile
Where octreotide and lanreotide act mainly through SSTR2, pasireotide engages SSTR1, 2, 3 and especially SSTR5. Targeting SSTR5 lets it suppress ACTH secretion in corticotroph tumors, which is why it is used in Cushing's disease.
Design trade-offs
The wider receptor coverage that gives pasireotide its distinct indication also alters its metabolic effect on glucose regulation compared with older analogs. It is a frequently cited example of how receptor-subtype selectivity shapes a peptide drug's clinical niche.
FAQ about Pasireotide
What is Pasireotide?+
Pasireotide is a synthetic cyclohexapeptide somatostatin analog with roughly 40-fold greater affinity for somatostatin receptor 5 than earlier analogs. This broader receptor profile underlies its approval for Cushing's disease and acromegaly. Content here is educational only.
Is Pasireotide an approved medicine?+
Pasireotide: Approved for Cushing's disease and acromegaly. Always follow licensed medical guidance for approved products.
What is the typical length of Pasireotide?+
Pasireotide is commonly described as approximately 6 amino acids (Somatostatin analog).